New drug combo shows promise in controlling tough hodgkin lymphoma after transplant
NCT ID NCT03057795
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This study tests whether giving two immunotherapy drugs, nivolumab and brentuximab vedotin, after a stem cell transplant can help keep high-risk Hodgkin lymphoma from coming back. The trial includes 62 patients whose lymphoma had returned or did not respond to earlier treatments. The goal is to improve the chance of living without the cancer progressing for at least 18 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.